#United States #San Francisco #diabetes #Cirius Therapeutics #azemiglitazone

Cirius Therapeutics Set to Present at WuXi Global Forum

Company Overview
Cirius Therapeutics, Inc., a cutting-edge clinical-stage pharmaceutical company, dedicated to addressing diseases linked with insulin resistance, including metabolic disorders like Type 2 diabetes and obesity, has exciting news. The company is gearing up for a presentation at the WuXi Global Forum, which aligns with the prestigious J.P. Morgan Healthcare Conference in San Francisco.

Key Presenters
At this event, Robert Beardsley, Ph.D., the President and CEO of Cirius, alongside Jerry Colca, Ph.D., the Chief Scientific Officer, will host a significant roundtable discussion titled, "Unlocking the Next Frontier of Metabolic Medications in Combination with the GLP-1s." This discussion is scheduled for January 14, 2025, from 5:00 PM to 6:00 PM PT at the Hilton Union Square.

Focus of Discussion
The roundtable aims to highlight the benefits of Cirius' promising oral insulin sensitizer, azemiglitazone (also known as MSDC-0602K). Drs. Beardsley and Colca will present research on how azemiglitazone may enhance the efficacy of GLP-1s for treating Type 2 diabetes (T2D) and obesity. Preliminary Phase 2 clinical trials have indicated that azemiglitazone significantly improves glycemic control in patients already undergoing GLP-1 therapy. This presents a crucial solution for numerous patients battling T2D who struggle to meet their HbA1c targets.

Clinical Insights
Azemiglitazone has shown success in preclinical studies, improving body composition and the overall quality of weight loss in combination with GLP-1 treatments. This is particularly relevant for patients facing the dual challenges of managing diabetes and obesity. By targeting insulin resistance at the mitochondrial level, azemiglitazone could potentially redefine treatment standards for metabolic dysfunctions.

Cirius’ Mission
Cirius Therapeutics is committed to pioneering innovative therapeutics that aim to reverse the pathology of chronic metabolic diseases caused by insulin resistance. With azemiglitazone, the company's lead product candidate, Cirius envisions creating a once-daily oral treatment that selectively inhibits mitochondrial targets to maintain metabolic equilibrium and restore appropriate insulin response. This represents a hopeful avenue for improving not only glycemic control but also liver function and managing complications arising from metabolic dysfunctions.

Significance of Azemiglitazone
Azemiglitazone has successfully completed seven clinical trials in the U.S., including comprehensive Phase 2 studies focusing on subjects with metabolic dysfunction. Distinctly, it has demonstrated increased lean muscle mass and advantageous transformations in adipose tissue distribution, prioritizing the development of metabolically favorable white and brown fats.

By engaging in focused discussions during the WuXi Global Forum, Cirius Therapeutics aims to secure its place at the forefront of metabolic innovations, potentially benefiting millions affected by T2D and obesity. The anticipated Phase 3 clinical trials will further illuminate the potential of azemiglitazone to deliver on the promise of effective insulin sensitizers and bring much-needed relief to patients entrenched in chronic metabolic battles.
For more information about Cirius Therapeutics and its groundbreaking work, visit CiriusTx.com.